Cell-clearing drug eases signs of bone marrow aging in mice
Eight doses of 753b in aged mice reduced age-related gene-activity patterns and restored more balanced blood-cell production compared with vehicle controls.
Limit: Treatment lasted only three weeks
Stake: An author founded Dialectic Therapeutics and holds shares in it.
Edited by Boris Djordjevic · AgingResearch.News
In a randomized animal experiment, 22-month-old C57BL/6 mice received the experimental compound 753b or an inactive vehicle. Researchers gave eight injections of 5 milligrams per kilogram of body weight, three days apart, and collected tissues seven days after the final dose. The compound cleared senescent cells—cells that had stopped dividing—and reduced age-related gene-activity patterns in blood-forming stem cells. It also suppressed inflammatory signals from blood-forming cells and surrounding support cells, without major changes in the mix of support cells.
In transplantation experiments, marrow from 100-week-old mice treated with 753b for three weeks produced a more balanced mix of blood cells in recipient mice than marrow from vehicle-treated old mice. The balance resembled that produced by marrow from young donors.
Why it matters
Aging can impair blood formation and increase susceptibility to anemia, infections and blood cancers. The work addresses whether clearing senescent cells can help restore communication between blood-forming stem cells and their surroundings.
Caveats
These were experiments in mice, not tests of health benefits in people. The report is a preprint and has not been peer-reviewed.
- Compound 753b
- BCL2
- BCL2L1
- Cellular senescence
- Senescent cells
- Aging-associated transcriptional signatures in HSCs
The paper
Targeting cellular senescence alleviates bone marrow aging
University of Florida Health
bioRxiv, Jul 17, 2026, Open access, Preprint, not peer-reviewed
Comments
Be the first to comment.